Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Alnylam Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Alnylam Pharmaceuticals, Inc.’s stock price such as:

• Alnylam Pharmaceuticals, Inc.’s current stock price and volume
• Why Alnylam Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ALNY from analysts
• ALNY’s stock price momentum as measured by its relative strength

About Alnylam Pharmaceuticals, Inc. (ALNY)

Before we jump into Alnylam Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Want to learn more about Alnylam Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alnylam Pharmaceuticals, Inc..

Alnylam Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of June 24, 2024, 4:00 PM, CST, Alnylam Pharmaceuticals, Inc.’s stock price was $222.90.

Alnylam Pharmaceuticals, Inc. is up 34.52% from its previous closing price of $165.70.

During the last market session, Alnylam Pharmaceuticals, Inc.’s stock traded between $158.38 and $166.76. Currently, there are 126.14 million shares of Alnylam Pharmaceuticals, Inc. stock available for purchase.

Unfortunately, Alnylam Pharmaceuticals, Inc.’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Alnylam Pharmaceuticals, Inc. Stock Price History

Alnylam Pharmaceuticals, Inc.’s (ALNY) price is currently up 50.17% so far this month.

During the month of June, Alnylam Pharmaceuticals, Inc.’s stock price has reached a high of $231.64 and a low of $147.25.

Over the last year, Alnylam Pharmaceuticals, Inc. has hit prices as high as $218.88 and as low as $141.98. Year to date, Alnylam Pharmaceuticals, Inc.’s stock is down 6.21%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alnylam Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 21, 2024, there were 11 analysts who downgraded Alnylam Pharmaceuticals, Inc.’s stock and 8 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Alnylam Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Alnylam Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Alnylam Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alnylam Pharmaceuticals, Inc. (ALNY) by visiting AAII Stock Evaluator.

Relative Price Strength of Alnylam Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 21, 2024, Alnylam Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -5.72%, which translates to a Momentum Score of 49 and is considered to be Average.

Want to learn more about how Alnylam Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alnylam Pharmaceuticals, Inc. Stock Price: Bottom Line

As of June 24, 2024, Alnylam Pharmaceuticals, Inc.’s stock price is $222.90, which is up 34.52% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Alnylam Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.